Schizophrenia Management: An Update
Journal Title: Nepal Journal of Neuroscience - Year 2006, Vol 3, Issue 1
Abstract
Schizophrenia is the most disabling psychiatric disorder and one of the world’s top ten causes of long- term disability, affecting 1% of the population worldwide. Traditional or typical antipsychotics appear to act principally on dopamine(D2) receptors and they relieve mainly the positive symptoms in approximately 75% of the patients and produce much less improvement in negative symptoms. Unfortunately, all of them produce extrapyramidal side effects(EPS) to a varying degree. Newer antipsychotics (second generation or atypical ) appear to have additional blocking action on serotonin receptors, are more likely to relieve negative symptoms and are relatively free from EPS seen with typical/first generation neuroleptics.In this review, the efficacy of the novel atypical antipsychotics on the resistant schizophrenia is discussed with an emphasis on the future medication which are claimed to be more effective in the management of schizophrenia. These medicines are still in the various stages of clinical testing and development.
Authors and Affiliations
Parul Lakhanpal, MD
Keywords
Related Articles
- EP ID EP382002
- DOI -
- Views 108
- Downloads 0
Cockayne Syndrome
A case of Cockayne syndrome in a nine-year-old boy is reported. The clinical course of the case is described and pertinent literature is reviewed.
Intradiploic Epidermoid Cyst Presenting as a Cranial Dermal Sinus: A Diagnostic Dilemma
Small superficial epidermoid and dermoid inclusion cysts are commonly encountered as “lumps and bumps” in the scalp and at the orbital rim. Their deeper-sited intracranial variants are uncommon however, accounting for le...
Risk Factor Analysis on the predictors of the Transsphenoidal Pituitary Surgery on Macroadenomas: A Multivariate Logistic Regression Analysis
Original article
Nepal Journal of Neuroscience 2014 Volume I
N/A
Reflections on Medical Students’ Dimensions
Medical Student Section